Shanghai Yingli Pharmaceutical Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Shanghai Yingli Science and Technology Co., Ltd. (to 2015)
0
Ending by 2030
Sep 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 17 US 12,799,132 Crystal Form of URAT1 Inhibitor Puliginurad and Preperation Thereof
- 2 terms have ended since Aug 23, 2026
- Oct 16 US 10,100,016 Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof · lapsed on the fee record
- Sep 20 US 11,447,490 Aromatic Heterocyclic Substituted Olefin Compound, Preparation Method for Same, Pharmaceutical Composition of Same, and Applications Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,745,321 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof In force · USPTO record | In force | USPTO record | |
| US 9,656,996 | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof In force · USPTO record | In force | USPTO record | |
| US 10,100,015 | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,466,003 | Nitrogenous Heterocyclic Aromatic Compound, Preparation Method Therefor, Pharmaceutical Composition Thereof, and Application Thereof In force · High confidence | In force | High confidence | |
| US 11,168,072 | Crystal Form of Morpholino Quinazoline Compound, Preparation Method Therefor and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,584,745 | Aromatic Heterocyclic Compound, Intermediate Thereof, Preparation Method Therefor, and Pharmaceutical Composition and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,505,542 | Preparation method for morpholinquinazoline compound and intermediates thereof In force · USPTO record | In force | USPTO record | |
| US 12,799,132 | Crystal Form of URAT1 Inhibitor Puliginurad and Preperation Thereof In force · High confidence | In force | High confidence | |
| US 12,655,140 | Compound containing structure of a heteroaromatic ring, pharmaceutical composition thereof and application thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 patent in force now held by others · 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded